孕21至22周产前皮质类固醇暴露与新生儿生存及无主要疾病生存的关系
这项回顾性队列研究纳入2016年1月1日至2019年12月31日在美国国立儿童健康与人类发展研究所新生儿研究网络中心出生、胎龄22 0/7至23 6/7周的431例婴儿,比较22 6/7周前产前皮质类固醇暴露(无、部分、完整)与结局的关系。完整暴露组130例(53.9%)存活至出院,部分暴露组30例(37.5%),无暴露组239例(35.5%)。完整暴露 vs 无暴露的出院生存aOR为1.95(95%CI 1.07-3.56),无主要疾病生存aOR为2.74(95%CI 1.19-6.30)。作者认为,在考虑积极治疗时,22 6/7周前使用产前皮质类固醇可能有益。
要点
- 完整产前皮质类固醇暴露组出院生存130/241(53.9%),无暴露组239例中35.5%存活,aOR 1.95(95%CI 1.07-3.56)。
- 完整暴露组无主要疾病生存aOR 2.74(95%CI 1.19-6.30),优于无暴露组。
- 部分暴露组出院生存30/80(37.5%),无暴露组为35.5%,完整暴露组为53.9%。
- 研究纳入431例胎龄22 0/7至23 6/7周接受重症监护的婴儿,其中17例在21周暴露于产前皮质类固醇。
- 作者认为,在考虑积极治疗时,22 6/7周前使用产前皮质类固醇可能有益。
适用人群与场景
- 2016年1月1日至2019年12月31日在美国国立儿童健康与人类发展研究所新生儿研究网络中心出生、胎龄22 0/7至23 6/7周的婴儿。
- 排除未接受重症监护的婴儿及在胎龄22 6/7周后暴露于产前皮质类固醇的婴儿。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量431例(平均[SD]胎龄22.6[0.5]周;232例[53.8%]为男孩);暴露分类:无产前皮质类固醇110例(25.5%)、部分暴露80例(18.6%)、完整暴露241例(55.9%);17例在胎龄21周暴露于产前皮质类固醇。
- 主要终点(存活至出院):完整暴露组130例(53.9%)vs 部分暴露组30例(37.5%)vs 无暴露组239例中35.5%;完整暴露 vs 无暴露的aOR 1.95(95%CI 1.07-3.56)。
- 主要次要终点(无主要新生儿疾病生存):完整暴露 vs 无暴露的aOR 2.74(95%CI 1.19-6.30)。
- 回归模型调整了胎龄、性别、种族、母亲教育程度、小于胎龄儿状态、分娩方式、多胎、胎膜早破、出生年份和新生儿研究网络中心。
证据类型、等级与局限
- 证据类型:回顾性队列研究;作者结论认为,在考虑积极治疗时,22 6/7周前使用产前皮质类固醇可能有益。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,在考虑积极治疗时,对胎龄22 6/7周及以下的患者使用产前皮质类固醇可能有益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The provision of antenatal corticosteroids to pregnant patients at gestational age (GA) 22 6/7 weeks or less remains controversial and lacks support from randomized clinical trials.
OBJECTIVE: To compare rates of survival and survival without major morbidities among infants born at GA 22 0/7 to 23 6/7 weeks after exposure to antenatal steroids at 22 6/7 weeks' gestation or less vs no exposure to antenatal steroids.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled infants born at GA 22 0/7 to 23 6/7 weeks between January 1, 2016, and December 31, 2019, at centers in the National Institute of Child Health and Human Development Neonatal Research Network. Infants who did not receive intensive care and infants with antenatal steroid exposure after GA 22 6/7 weeks were excluded.
EXPOSURE: Infants were classified as having no, partial, or complete exposure to antenatal steroids.
MAIN OUTCOMES AND MEASURES: The primary outcome was survival to discharge. The main secondary outcome was survival without major neonatal morbidity. The associations of differential exposures to antenatal steroids with outcomes were evaluated using logistic regression, adjusting for GA, sex, race, maternal education, small for GA status, mode of delivery, multiple birth, prolonged rupture of membranes, year of birth, and Neonatal Research Network center.
RESULTS: A total of 431 infants (mean [SD] GA, 22.6 [0.5] weeks; 232 [53.8%] boys) were included, with 110 infants (25.5%) receiving no antenatal steroids, 80 infants (18.6%) receiving partial antenatal steroids, and 241 infants (55.9%) receiving complete antenatal steroids. Seventeen infants were exposed to antenatal steroids at GA 21 weeks. Among infants exposed to complete antenatal steroids, 130 (53.9%) survived to discharge, compared with 30 infants (37.5%) with partial antenatal steroid exposure and 239 infants (35.5%) with no antenatal steroids. Infants born after complete antenatal steroid exposure, compared with those without antenatal steroid exposure, were more likely to survive to discharge (adjusted odds ratio [aOR], 1.95 [95% CI, 1.07-3.56]) and to survive without major morbidity (aOR, 2.74 [95% CI, 1.19-6.30]).
CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, among infants born between GA 22 0/7 and 23 6/7 weeks who received intensive care, exposure to a complete course of antenatal steroids at GA 22 6/7 weeks or less was independently associated with greater odds of survival and survival without major morbidity. These data suggest that the use of antenatal steroids in patients at GA 22 6/7 weeks or less could be beneficial when active treatment is considered.
参考来源
- Chawla S, Wyckoff MH, Rysavy MA, et al. Association of Antenatal Steroid Exposure at 21 to 22 Weeks of Gestation With Neonatal Survival and Survival Without Morbidities. JAMA Netw Open. 2022. PMID: 36156145. doi:10.1001/jamanetworkopen.2022.33331
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。